



Conquering hepatitis C in our time

Change in Share Capital

Rehovot, Israel; Sunday 13 November 2005: XTL Biopharmaceuticals Ltd ("XTLbio") (LSE: XTL; NASDAQ: XTLB; TASE: XTL) would like to inform the Tel Aviv Stock Exchange ("TASE") that since our registration on the TASE on 12 July 2005 until 31 October 2005, XTLbio's share capital has increased by a total amount of 1,819,747 shares.

On 31 October 2005 the number of issued and outstanding shares was 171,003,001.

Contacts:

XTLbio

Jonathan Burgin, Chief Financial Officer

Tel: +972 8 930 4440

About XTL Biopharmaceuticals Ltd.

Established in 1993, XTL Biopharmaceuticals Ltd. (LSE: XTL; NASDAQ: XTLB; TASE: XTL) is a biopharmaceutical company engaged in the acquisition, development and commercialization of pharmaceutical products for the treatment of infectious diseases, particularly the prevention and treatment of hepatitis B and C.